Company Profile
Glaukos Corporation Stock Price, News & Analysis
- Ticker:
- GKOS
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Stock performance
170.99 USD (+0.04%)
Close
Last updated: August 6, 2026
6.51B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, GKOS was little changed and closed at $170.99. No new same-company headline was identified in the current news window.
Company overview
Business overview
Glaukos is a medical technology company focused on ophthalmology, glaucoma devices, and corneal health. Its business is centered on procedure-based eye-care technologies rather than therapeutics.
Geographic Base and Sector Classification
Glaukos is headquartered in the United States and listed on NYSE. It sits in ophthalmic medtech rather than biotechnology.
Business Model Characteristics
The company depends on device adoption, surgeon acceptance, and the ability to expand across eye-care procedures. Investors watch product launches, clinical adoption, and margin trends.
Position Within the Biotechnology Landscape
Glaukos occupies a high-quality ophthalmic-device niche within healthcare innovation. It is not biotech, but it is a procedure-driven growth stock with meaningful clinical relevance.
Future catalysts
Glaukos’s catalysts are iStent / iDose commercialization, glaucoma adoption, and continued procedural growth in ophthalmology. The market will care about whether the device base keeps broadening.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Glaukos Corporation (GKOS)?
Glaukos Corporation (GKOS) most recently closed at 170.99 USD, a +0.04% move versus the previous session.
What is the market cap of Glaukos Corporation (GKOS)?
Glaukos Corporation currently has a market capitalization of 6.51B USD on BioPharmSignal.
What does Glaukos Corporation do?
Glaukos is a medical technology company focused on ophthalmology, glaucoma devices, and corneal health. Its business is centered on procedure-based eye-care technologies rather than therapeutics.
On which exchange is GKOS stock listed?
Glaukos Corporation (GKOS) is associated with NYSE, United States, Biopharma.
What is Glaukos?
Glaukos’s catalysts are iStent / iDose commercialization, glaucoma adoption, and continued procedural growth in ophthalmology.
Which conditions is Glaukos Corporation targeting with Glaukos?
Glaukos Corporation is associated with ophthalmology based on its company overview and current catalyst commentary.
How does Glaukos Corporation describe recent progress with Glaukos?
Glaukos’s catalysts are iStent / iDose commercialization, glaucoma adoption, and continued procedural growth in ophthalmology.
What future catalysts are investors watching for Glaukos Corporation?
Glaukos’s catalysts are iStent / iDose commercialization, glaucoma adoption, and continued procedural growth in ophthalmology. The market will care about whether the device base keeps broadening.